Symbols / BNGO
BNGO Chart
About
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 10.65M |
| Enterprise Value | 6.81M | Income | -38.59M | Sales | 28.72M |
| Book/sh | 5.12 | Cash/sh | 2.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 98 | IPO | — |
| P/E | — | Forward P/E | -0.44 | PEG | — |
| P/S | 0.37 | P/B | 0.21 | P/C | — |
| EV/EBITDA | -0.42 | EV/Sales | 0.24 | Quick Ratio | 1.14 |
| Current Ratio | 2.12 | Debt/Eq | 34.53 | LT Debt/Eq | — |
| EPS (ttm) | -12.83 | EPS next Y | -2.49 | EPS Growth | — |
| Revenue Growth | 21.30% | Earnings | 2026-03-11 | ROA | -19.31% |
| ROE | -78.22% | ROIC | — | Gross Margin | 45.97% |
| Oper. Margin | -115.89% | Profit Margin | -134.36% | Shs Outstand | 9.68M |
| Shs Float | 9.13M | Short Float | 11.17% | Short Ratio | 4.44 |
| Short Interest | — | 52W High | 6.07 | 52W Low | 1.06 |
| Beta | 1.69 | Avg Volume | 228.84K | Volume | 100.94K |
| Target Price | $7.50 | Recom | None | Prev Close | $1.10 |
| Price | $1.10 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.50
Mean price target
2. Current target
$1.10
Latest analyst target
3. DCF / Fair value
$5.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.10
Low
$7.00
High
$8.00
Mean
$7.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-24 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-08-18 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2025-05-20 | up | Maxim Group | Hold → Buy | $8 |
| 2025-04-09 | init | HC Wainwright & Co. | — → Buy | $10 |
| 2025-04-02 | main | Scotiabank | Sector Perform → Sector Perform | $4 |
| 2024-11-15 | down | Ladenburg Thalmann | Buy → Neutral | — |
| 2024-05-16 | main | BTIG | Buy → Buy | $2 |
| 2024-03-07 | main | Scotiabank | Sector Outperform → Sector Outperform | $6 |
| 2023-11-13 | down | Maxim Group | Buy → Hold | — |
| 2023-08-10 | main | BTIG | Buy → Buy | $10 |
- $30M Total Potential: Bionano Genomics Launches Strategic Public Offering with 5-Year Warrants - Stock Titan ue, 16 Sep 2025 07
- Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum - Yahoo Finance Fri, 22 Aug 2025 07
- How Low Can Bionano Genomics Stock Really Go? - Trefis Sun, 21 Dec 2025 08
- Volume Summary: Will BNGO stock benefit from upcoming earnings reports - Wall Street Watch & Fast Exit and Entry Strategy Plans - mfd.ru Sat, 14 Feb 2026 20
- Market Cool On Bionano Genomics, Inc.'s (NASDAQ:BNGO) Revenues - simplywall.st Fri, 30 Jan 2026 08
- Bionano Genomics stock price target raised to $11 from $10 at H.C. Wainwright - Investing.com Mon, 18 Aug 2025 07
- Bionano Genomics (BNGO) Upgraded to Buy as Future Prospects Brig - GuruFocus ue, 20 May 2025 07
- Bionano Genomics Q3 2025 Financial Results - TradingView hu, 13 Nov 2025 08
- New gene editing safety check uses Bionano tech to spot hidden DNA changes - Stock Titan Wed, 04 Feb 2026 08
- Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock - Yahoo Finance Mon, 08 Sep 2025 07
- How BNGO stock performs in interest rate cycles - July 2025 Analyst Calls & Stock Portfolio Risk Management - mfd.ru Mon, 16 Feb 2026 05
- Bionano Genomics Second Quarter 2025 Earnings: Beats Expectations - simplywall.st Sat, 16 Aug 2025 07
- HC Wainwright & Co. Initiates Coverage of Bionano Genomics (BNGO) with Buy Recommendation - Nasdaq Wed, 09 Apr 2025 07
- Bionano Genomics Inc (BNGO) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Cost ... - Yahoo Finance hu, 13 Nov 2025 08
- Bionano's OGM Test Gets $1,264 CMS Payment Rate for Genetic Testing | BNGO Stock News - Stock Titan Mon, 15 Sep 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 44000 | — | — | HOLMLIN R ERIK | Chief Executive Officer | — | 2024-06-03 00:00:00 | D |
| 1 | 16000 | — | — | OLDAKOWSKI MARK | Chief Operating Officer | — | 2024-06-03 00:00:00 | D |
| 2 | 16000 | — | — | CHAUBEY ALKA PH.D. | Officer | — | 2024-06-03 00:00:00 | D |
| 3 | 14500 | — | — | DIXON JONATHAN V | General Counsel | — | 2024-06-03 00:00:00 | D |
| 4 | 16000 | — | — | KAMA GULSEN | Chief Financial Officer | — | 2024-06-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -6.53M | -16.38M | 0.00 | -22.02K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.07 |
| NormalizedEBITDA | -64.30M | -143.50M | -120.57M | -73.55M |
| TotalUnusualItems | -31.08M | -78.02M | 0.00 | -301.00K |
| TotalUnusualItemsExcludingGoodwill | -31.08M | -78.02M | 0.00 | -301.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -112.02M | -232.49M | -132.60M | -72.44M |
| ReconciledDepreciation | 14.23M | 13.91M | 9.84M | 3.37M |
| ReconciledCostOfRevenue | 30.40M | 26.55M | 21.86M | 14.11M |
| EBITDA | -95.39M | -221.52M | -120.57M | -73.86M |
| EBIT | -109.61M | -235.43M | -130.41M | -77.22M |
| NetInterestIncome | -3.91M | -17.04M | 1.21M | -691.00K |
| InterestExpense | 2.37M | -3.00M | 298.00K | 927.00K |
| InterestIncome | 2.10M | 3.31M | 1.51M | 236.00K |
| NormalizedIncome | -87.46M | -170.86M | -132.60M | -72.16M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -112.02M | -232.49M | -132.60M | -72.44M |
| TotalExpenses | 107.05M | 173.34M | 159.50M | 95.08M |
| TotalOperatingIncomeAsReported | -103.98M | -215.25M | -131.70M | -77.10M |
| DilutedAverageShares | 1.87M | 569.00K | 495.30K | 482.67K |
| BasicAverageShares | 1.87M | 569.00K | 495.30K | 482.67K |
| DilutedEPS | -60.05 | -408.60 | -267.71 | -150.07 |
| BasicEPS | -60.05 | -408.60 | -267.71 | -150.07 |
| DilutedNIAvailtoComStockholders | -112.02M | -232.49M | -132.60M | -72.44M |
| NetIncomeCommonStockholders | -112.02M | -232.49M | -132.60M | -72.44M |
| NetIncome | -112.02M | -232.49M | -132.60M | -72.44M |
| NetIncomeIncludingNoncontrollingInterests | -112.02M | -232.49M | -132.60M | -72.44M |
| NetIncomeContinuousOperations | -112.02M | -232.49M | -132.60M | -72.44M |
| TaxProvision | 33.00K | 62.00K | 1.88M | -5.72M |
| PretaxIncome | -111.98M | -232.43M | -130.71M | -78.15M |
| OtherIncomeExpense | -31.80M | -78.17M | -223.00K | -360.00K |
| OtherNonOperatingIncomeExpenses | -716.00K | -148.00K | -223.00K | -59.00K |
| SpecialIncomeCharges | -31.08M | -78.02M | 0.00 | -301.00K |
| OtherSpecialCharges | 3.38M | 301.00K | ||
| ImpairmentOfCapitalAssets | 19.68M | 77.28M | 0.00 | |
| RestructuringAndMergernAcquisition | 8.02M | 741.00K | ||
| NetNonOperatingInterestIncomeExpense | -3.91M | -17.04M | 1.21M | -691.00K |
| TotalOtherFinanceCost | 3.64M | 23.35M | ||
| InterestExpenseNonOperating | 2.37M | -3.00M | 298.00K | 927.00K |
| InterestIncomeNonOperating | 2.10M | 3.31M | 1.51M | 236.00K |
| OperatingIncome | -76.28M | -137.22M | -131.70M | -77.10M |
| OperatingExpense | 76.66M | 146.79M | 137.64M | 80.97M |
| ResearchAndDevelopment | 24.80M | 54.03M | 49.05M | 22.48M |
| SellingGeneralAndAdministration | 51.85M | 92.76M | 88.60M | 58.49M |
| GrossProfit | 380.00K | 9.57M | 5.95M | 3.87M |
| CostOfRevenue | 30.40M | 26.55M | 21.86M | 14.11M |
| TotalRevenue | 30.78M | 36.12M | 27.80M | 17.98M |
| OperatingRevenue | 30.78M | 36.12M | 27.80M | 17.98M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 1.87M | 762.53K | 495.30K | 482.67K |
| ShareIssued | 1.87M | 762.53K | 495.30K | 482.67K |
| NetDebt | 51.85M | |||
| TotalDebt | 6.93M | 9.61M | 11.67M | 10.70M |
| TangibleBookValue | 25.67M | 62.19M | 130.97M | 254.12M |
| InvestedCapital | 35.38M | 96.16M | 249.40M | 337.12M |
| WorkingCapital | 2.15M | 40.09M | 121.41M | 250.57M |
| NetTangibleAssets | 25.67M | 62.19M | 130.97M | 254.12M |
| CapitalLeaseObligations | 6.93M | 9.61M | 11.67M | 10.70M |
| CommonStockEquity | 35.38M | 96.16M | 249.40M | 337.12M |
| TotalCapitalization | 35.38M | 96.16M | 249.40M | 337.12M |
| TotalEquityGrossMinorityInterest | 35.38M | 96.16M | 249.40M | 337.12M |
| StockholdersEquity | 35.38M | 96.16M | 249.40M | 337.12M |
| GainsLossesNotAffectingRetainedEarnings | 27.00K | 23.00K | -1.12M | -539.00K |
| OtherEquityAdjustments | 27.00K | 23.00K | -1.12M | -539.00K |
| RetainedEarnings | -693.23M | -581.21M | -348.71M | -216.12M |
| AdditionalPaidInCapital | 728.57M | 677.34M | 599.23M | 553.75M |
| CapitalStock | 0.00 | 0.00 | 3.00K | 29.00K |
| CommonStock | 0.00 | 0.00 | 3.00K | 29.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 41.30M | 118.25M | 58.10M | 39.98M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.95M | 18.22M | 22.22M | 18.14M |
| OtherNonCurrentLiabilities | 10.89M | 12.97M | 9.07M | |
| NonCurrentDeferredLiabilities | 267.00K | 154.00K | 127.00K | 146.00K |
| NonCurrentDeferredRevenue | 267.00K | 154.00K | 127.00K | 146.00K |
| LongTermDebtAndCapitalLeaseObligation | 3.68M | 7.17M | 9.12M | 8.93M |
| LongTermCapitalLeaseObligation | 3.68M | 7.17M | 9.12M | 8.93M |
| CurrentLiabilities | 37.34M | 100.03M | 35.88M | 21.84M |
| OtherCurrentLiabilities | 20.36M | 78.34M | 9.38M | 175.00K |
| CurrentDeferredLiabilities | 1.15M | 800.00K | 888.00K | 1.51M |
| CurrentDeferredRevenue | 1.15M | 800.00K | 888.00K | 1.51M |
| CurrentDebtAndCapitalLeaseObligation | 3.25M | 2.44M | 2.54M | 1.77M |
| CurrentCapitalLeaseObligation | 3.25M | 2.44M | 2.54M | 1.77M |
| CurrentDebt | 69.80M | |||
| OtherCurrentBorrowings | 69.80M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.98M | 5.03M | 7.00M | 4.53M |
| CurrentProvisions | 276.00K | 391.00K | ||
| PayablesAndAccruedExpenses | 10.33M | 13.04M | 16.07M | 14.04M |
| CurrentAccruedExpenses | 2.64M | 1.55M | 2.71M | 2.59M |
| InterestPayable | 0.00 | |||
| Payables | 7.69M | 11.48M | 13.36M | 11.45M |
| TotalTaxPayable | 729.00K | 1.10M | 825.00K | 677.00K |
| AccountsPayable | 6.96M | 10.38M | 12.53M | 10.77M |
| TotalAssets | 76.67M | 214.40M | 307.50M | 377.10M |
| TotalNonCurrentAssets | 37.18M | 74.28M | 150.20M | 104.69M |
| OtherNonCurrentAssets | 3.15M | 7.83M | 2.81M | 749.00K |
| GoodwillAndOtherIntangibleAssets | 9.70M | 33.97M | 118.43M | 83.00M |
| OtherIntangibleAssets | 9.70M | 33.97M | 41.14M | 26.84M |
| Goodwill | 0.00 | 77.29M | 56.16M | |
| NetPPE | 24.32M | 32.48M | 28.96M | 20.93M |
| AccumulatedDepreciation | -26.86M | -19.08M | -13.08M | -9.07M |
| GrossPPE | 51.18M | 51.56M | 42.03M | 30.01M |
| Leases | 3.33M | 3.75M | 4.00M | 2.67M |
| OtherProperties | 45.14M | 44.83M | 36.41M | 26.51M |
| MachineryFurnitureEquipment | 2.72M | 2.98M | 1.62M | 819.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 39.49M | 140.12M | 157.30M | 272.41M |
| OtherCurrentAssets | 1.32M | 976.00K | 2.41M | 1.38M |
| RestrictedCash | 11.00M | 35.12M | ||
| PrepaidAssets | 1.80M | 4.70M | 4.44M | 2.72M |
| Inventory | 11.12M | 22.89M | 29.76M | 12.39M |
| FinishedGoods | 17.39M | 6.08M | ||
| WorkInProcess | 7.05M | 1.66M | ||
| RawMaterials | 5.32M | 4.65M | ||
| Receivables | 4.77M | 9.66M | 7.50M | 5.32M |
| AccruedInterestReceivable | 22.00K | 342.00K | 474.00K | 387.00K |
| AccountsReceivable | 4.75M | 9.32M | 7.02M | 4.93M |
| AllowanceForDoubtfulAccountsReceivable | -157.00K | -483.00K | -293.00K | -690.00K |
| GrossAccountsReceivable | 4.91M | 9.80M | 7.32M | 5.62M |
| CashCashEquivalentsAndShortTermInvestments | 9.47M | 66.77M | 113.19M | 250.61M |
| OtherShortTermInvestments | 302.00K | 48.82M | 108.09M | 226.04M |
| CashAndCashEquivalents | 9.17M | 17.95M | 5.09M | 24.57M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -69.03M | -126.87M | -128.12M | -73.39M |
| RepaymentOfDebt | -66.06M | -9.05M | -36.00K | -15.01M |
| IssuanceOfDebt | 18.00M | 80.00M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 44.43M | 57.70M | 23.13M | 342.71M |
| CapitalExpenditure | -103.00K | -1.69M | -3.30M | -1.46M |
| InterestPaidSupplementalData | 10.65M | 1.65M | 298.00K | 1.91M |
| EndCashPosition | 9.57M | 18.35M | 5.49M | 24.57M |
| BeginningCashPosition | 18.35M | 5.49M | 24.57M | 38.45M |
| EffectOfExchangeRateChanges | -7.00K | 65.00K | -38.00K | 0.00 |
| ChangesInCash | -8.77M | 12.79M | -19.04M | -13.88M |
| FinancingCashFlow | -13.69M | 113.81M | 23.01M | 336.11M |
| CashFlowFromContinuingFinancingActivities | -13.69M | 113.81M | 23.01M | 336.11M |
| NetOtherFinancingCharges | -10.07M | -14.96M | -578.00K | -1.70M |
| ProceedsFromStockOptionExercised | 15.00K | 130.00K | 493.00K | 10.11M |
| NetCommonStockIssuance | 44.43M | 57.70M | 23.13M | 342.71M |
| CommonStockIssuance | 44.43M | 57.70M | 23.13M | 342.71M |
| NetIssuancePaymentsOfDebt | -48.06M | 70.95M | -36.00K | -15.01M |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | 0.00 | |||
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | -48.06M | 70.95M | -36.00K | -15.01M |
| LongTermDebtPayments | -66.06M | -9.05M | -36.00K | -15.01M |
| LongTermDebtIssuance | 18.00M | 80.00M | 0.00 | 0.00 |
| InvestingCashFlow | 73.84M | 24.16M | 82.77M | -278.06M |
| CashFlowFromContinuingInvestingActivities | 73.84M | 24.16M | 82.77M | -278.06M |
| NetOtherInvestingChanges | 694.00K | -607.00K | ||
| NetInvestmentPurchaseAndSale | 73.94M | 25.75M | 116.69M | -226.91M |
| SaleOfInvestment | 306.96M | 137.02M | 200.89M | 86.48M |
| PurchaseOfInvestment | -233.02M | -111.26M | -84.19M | -313.39M |
| NetBusinessPurchaseAndSale | 0.00 | 96.00K | -31.34M | -49.09M |
| SaleOfBusiness | 0.00 | 96.00K | 0.00 | |
| PurchaseOfBusiness | 0.00 | -31.34M | -49.09M | |
| NetIntangiblesPurchaseAndSale | 0.00 | -102.00K | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -102.00K | 0.00 | |
| NetPPEPurchaseAndSale | -103.00K | -1.69M | -3.17M | -1.46M |
| SaleOfPPE | 0.00 | 26.00K | 0.00 | |
| PurchaseOfPPE | -103.00K | -1.69M | -3.20M | -1.46M |
| OperatingCashFlow | -68.92M | -125.18M | -124.82M | -71.93M |
| CashFlowFromContinuingOperatingActivities | -68.92M | -125.18M | -124.82M | -71.93M |
| InterestPaidCFO | 0.00 | -1.24M | ||
| ChangeInWorkingCapital | 4.40M | -14.77M | -27.94M | -7.65M |
| ChangeInOtherCurrentAssets | 4.68M | -5.02M | -1.13M | -647.00K |
| ChangeInPayablesAndAccruedExpense | -5.41M | -4.52M | 2.31M | 10.74M |
| ChangeInAccruedExpense | -1.99M | -2.52M | 366.00K | 3.96M |
| ChangeInPayable | -3.42M | -2.00M | 1.95M | 6.78M |
| ChangeInAccountPayable | -3.42M | -2.00M | 1.95M | 6.78M |
| ChangeInPrepaidAssets | 1.58M | 1.21M | -3.20M | -1.32M |
| ChangeInInventory | -587.00K | -4.15M | -23.68M | -15.93M |
| ChangeInReceivables | 4.14M | -2.30M | -2.25M | -493.00K |
| ChangesInAccountReceivables | 4.14M | -2.30M | -2.25M | -493.00K |
| OtherNonCashItems | -9.20M | 16.42M | 794.00K | 1.48M |
| StockBasedCompensation | 9.74M | 15.18M | 22.42M | 9.72M |
| UnrealizedGainLossOnInvestmentSecurities | -8.12M | -575.00K | ||
| ProvisionandWriteOffofAssets | 649.00K | 0.00 | ||
| AssetImpairmentCharge | 26.91M | 77.28M | 0.00 | 0.00 |
| AmortizationOfSecurities | -1.32M | -539.00K | 638.00K | 329.00K |
| DeferredTax | 0.00 | 1.76M | -5.78M | |
| DeferredIncomeTax | 0.00 | 1.76M | -5.78M | |
| DepreciationAmortizationDepletion | 14.23M | 13.91M | 9.84M | 3.37M |
| DepreciationAndAmortization | 14.23M | 13.91M | 9.84M | 3.37M |
| Depreciation | 14.23M | 13.91M | 9.84M | 3.37M |
| OperatingGainsLosses | 6.45M | 405.00K | 270.00K | 273.00K |
| GainLossOnInvestmentSecurities | 14.00K | 23.00K | 66.00K | |
| GainLossOnSaleOfPPE | 3.06M | 382.00K | 204.00K | 568.00K |
| NetIncomeFromContinuingOperations | -112.02M | -232.49M | -132.60M | -72.44M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BNGO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|